Investment analysts at Lifesci Capital boosted their Q1 2025 earnings per share estimates for shares of Corbus Pharmaceuticals in a research note issued on Tuesday, March 11th. Lifesci Capital analyst ...

Find the latest Corbus Pharmaceuticals Holdings CRBP analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Corbus Pharmaceuticals Highlights Data From Its First US-Based Trial Of Lead Cancer Drug Candidate Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Free ... their previous forecast of ($1.33). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock.

Fintel reports that on February 28, 2025, William Blair initiated coverage of Corbus Pharmaceuticals Holdings (NasdaqCM:CRBP) with a Outperform recommendation. Analyst Price Forecast Suggests 690. ...

This was the stock's second consecutive day of losses.

Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) stock has reached a 52-week low, trading at $7.87, with InvestingPro data showing the stock is currently trading below its Fair... In a recent ...

Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the Earnings Calendar to see dates for upcoming earnings announcements.

CRBP) with a Outperform recommendation. As of February 19, 2025, the average one-year price target for Corbus Pharmaceuticals Holdings is $57.91/share. The forecasts range from a low of $35.35 to ...